BACKGROUND: Free fatty acids (FFAs) affect insulin signaling and are implicated in the pathogenesis of insulin resistance and atherosclerosis. Inflammatory cytokines such as interleukin-6 (IL-6) increase lipolysis and thus levels of FFAs. We hypothesized that increased IL-6 concentrations are associated with increased FFAs resulting in insulin resistance and atherosclerosis in rheumatoid arthritis (RA). METHODS: Clinical variables, serum FFAs and inflammatory cytokines, homeostasis model assessment for insulin resistance (HOMA-IR), and coronary artery calcium were measured in 166 patients with RA and 92 controls. We compared serum FFAs in RA and controls using Wilcoxon rank sum tests and further tested for multivariable association by adjusting for age, race, sex and BMI. Among patients with RA, we assessed the relationship between serum FFAs and inflammatory cytokines, HOMA-IR, and coronary artery calcium scores using Spearman correlation and multivariable regression analyses. RESULTS: Serum FFAs did not differ significantly in patients with RA and controls (0.56mmol/L [0.38-0.75] and 0.56mmol/L [0.45-0.70] respectively, p=0.75). Presence of metabolic syndrome was associated with significantly increased serum FFAs in both RA and controls (p=0.035 and p=0.025). In multivariable regression analysis that adjusted for age, race, sex and BMI, serum FFAs were associated with HOMA-IR (p=0.011), CRP (p=0.01), triglycerides (p=0.005) and Framingham risk score (p=0.048) in RA, but not with IL-6 (p=0.48) or coronary artery calcium score (p=0.62). CONCLUSIONS: Serum FFAs do not differ significantly in patients with RA and controls. FFAs may contribute to insulin resistance, but are not associated with IL-6 and coronary atherosclerosis in RA.
BACKGROUND:Free fatty acids (FFAs) affect insulin signaling and are implicated in the pathogenesis of insulin resistance and atherosclerosis. Inflammatory cytokines such as interleukin-6 (IL-6) increase lipolysis and thus levels of FFAs. We hypothesized that increased IL-6 concentrations are associated with increased FFAs resulting in insulin resistance and atherosclerosis in rheumatoid arthritis (RA). METHODS: Clinical variables, serum FFAs and inflammatory cytokines, homeostasis model assessment for insulin resistance (HOMA-IR), and coronary artery calcium were measured in 166 patients with RA and 92 controls. We compared serum FFAs in RA and controls using Wilcoxon rank sum tests and further tested for multivariable association by adjusting for age, race, sex and BMI. Among patients with RA, we assessed the relationship between serum FFAs and inflammatory cytokines, HOMA-IR, and coronary artery calcium scores using Spearman correlation and multivariable regression analyses. RESULTS: Serum FFAs did not differ significantly in patients with RA and controls (0.56mmol/L [0.38-0.75] and 0.56mmol/L [0.45-0.70] respectively, p=0.75). Presence of metabolic syndrome was associated with significantly increased serum FFAs in both RA and controls (p=0.035 and p=0.025). In multivariable regression analysis that adjusted for age, race, sex and BMI, serum FFAs were associated with HOMA-IR (p=0.011), CRP (p=0.01), triglycerides (p=0.005) and Framingham risk score (p=0.048) in RA, but not with IL-6 (p=0.48) or coronary artery calcium score (p=0.62). CONCLUSIONS: Serum FFAs do not differ significantly in patients with RA and controls. FFAs may contribute to insulin resistance, but are not associated with IL-6 and coronary atherosclerosis in RA.
Authors: F C Arnett; S M Edworthy; D A Bloch; D J McShane; J F Fries; N S Cooper; L A Healey; S R Kaplan; M H Liang; H S Luthra Journal: Arthritis Rheum Date: 1988-03
Authors: Gerrit van Hall; Adam Steensberg; Massimo Sacchetti; Christian Fischer; Charlotte Keller; Peter Schjerling; Natalie Hiscock; Kirsten Møller; Bengt Saltin; Mark A Febbraio; Bente K Pedersen Journal: J Clin Endocrinol Metab Date: 2003-07 Impact factor: 5.958
Authors: Aruna D Pradhan; JoAnn E Manson; Jacques E Rossouw; David S Siscovick; Charles P Mouton; Nader Rifai; Robert B Wallace; Rebecca D Jackson; Mary B Pettinger; Paul M Ridker Journal: JAMA Date: 2002-08-28 Impact factor: 56.272
Authors: Miguel López-Yoldi; Marta Fernández-Galilea; Laura M Laiglesia; Eduardo Larequi; Jesús Prieto; J Alfredo Martínez; Matilde Bustos; Maria J Moreno-Aliaga Journal: J Lipid Res Date: 2014-10-28 Impact factor: 5.922
Authors: M J Ormseth; L L Swift; S Fazio; M F Linton; P Raggi; J F Solus; A Oeser; A Bian; T Gebretsadik; A Shintani; C M Stein Journal: Lupus Date: 2012-10-11 Impact factor: 2.911
Authors: Marta Fernández-Galilea; Patricia Pérez-Matute; Pedro L Prieto-Hontoria; J Alfredo Martinez; Maria J Moreno-Aliaga Journal: J Lipid Res Date: 2012-08-31 Impact factor: 5.922
Authors: Man Wai Tang; Frieda A Koopman; Jan P M Visscher; Maria J de Hair; Danielle M Gerlag; Paul Peter Tak Journal: Clin Rheumatol Date: 2016-11-02 Impact factor: 2.980
Authors: Hanna Mysliwiec; Ewa Harasim-Symbor; Anna Baran; Małgorzata Szterling-Jaworowska; Anna J Milewska; Adrian Chabowski; Iwona Flisiak Journal: Arch Med Sci Date: 2019-11-03 Impact factor: 3.318
Authors: Michelle J Ormseth; Cecilia P Chung; Annette M Oeser; Margery A Connelly; Tuulikki Sokka; Paolo Raggi; Joseph F Solus; James D Otvos; C Michael Stein Journal: Arthritis Res Ther Date: 2015-05-09 Impact factor: 5.156